elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q58802261-DC8B094E-C3FE-4CD7-9F79-46DB78FA4A2D
Q58802261-DC8B094E-C3FE-4CD7-9F79-46DB78FA4A2D
BestRank
Statement
http://www.wikidata.org/entity/statement/Q58802261-DC8B094E-C3FE-4CD7-9F79-46DB78FA4A2D
Alectinib in the treatment of ALK-positive non-small cell lung cancer: an update on its properties, efficacy, safety and place in therapy
P2860
Q58802261-DC8B094E-C3FE-4CD7-9F79-46DB78FA4A2D
BestRank
Statement
http://www.wikidata.org/entity/statement/Q58802261-DC8B094E-C3FE-4CD7-9F79-46DB78FA4A2D
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
06e8c6962c35fe0f7da3e9b098a7ca185d5227fb
P2860
Alectinib induces a durable (>15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis.